KR20160017607A - Oral anti-atopic preparations comprising rice prolamin - Google Patents
Oral anti-atopic preparations comprising rice prolamin Download PDFInfo
- Publication number
- KR20160017607A KR20160017607A KR1020150101592A KR20150101592A KR20160017607A KR 20160017607 A KR20160017607 A KR 20160017607A KR 1020150101592 A KR1020150101592 A KR 1020150101592A KR 20150101592 A KR20150101592 A KR 20150101592A KR 20160017607 A KR20160017607 A KR 20160017607A
- Authority
- KR
- South Korea
- Prior art keywords
- rice
- atopic
- dncb
- glutinous rice
- mice
- Prior art date
Links
- 235000007164 Oryza sativa Nutrition 0.000 title claims abstract description 126
- 235000009566 rice Nutrition 0.000 title claims abstract description 126
- 108060006613 prolamin Proteins 0.000 title claims abstract description 21
- 206010003645 Atopy Diseases 0.000 title claims description 27
- 240000007594 Oryza sativa Species 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title description 5
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 241000209094 Oryza Species 0.000 claims description 124
- 239000000284 extract Substances 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 8
- 230000000694 effects Effects 0.000 abstract description 32
- 206010012438 Dermatitis atopic Diseases 0.000 abstract description 25
- 201000008937 atopic dermatitis Diseases 0.000 abstract description 25
- 102000004169 proteins and genes Human genes 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 11
- 235000013305 food Nutrition 0.000 abstract description 3
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 24
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 24
- 238000011282 treatment Methods 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 201000004624 Dermatitis Diseases 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 10
- 239000000843 powder Substances 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 7
- 208000012657 Atopic disease Diseases 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000008591 skin barrier function Effects 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000037851 severe atopic dermatitis Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 238000010165 Scheffé test Methods 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Images
Classifications
-
- A23L1/29—
-
- A23L1/3002—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicines Containing Plant Substances (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
Abstract
Description
The present invention relates to an oral composition containing rice frylamine as an active ingredient and exhibiting anti-atopic activity.
Atopic dermatitis is a skin eczema disease that accompanies chronic itching with severe itching. It is a typical allergic disease with allergic asthma and allergic rhinitis. Until the 1970s, only 3% of children under 6 years of age were reported to be suffering from it, but recently, 20% of children and 1 ~ 3% of adults have been reported to develop atopic dermatitis.
The principle of treatment of atopic dermatitis is to remove the causative agents and factors to prevent the onset and worsening of symptoms, and to keep the skin durable and clean by using appropriate bath and moisturizer. When necessary to prevent secondary skin infections, topical steroids, topical calcineurin inhibitors, antihistamines, immunomodulators, antiviral agents, and the like are appropriately used. However, patients with severe atopic dermatitis who are unresponsive to such treatment or who have severe atopic dermatitis can take special treatment such as phototherapy, interferon gamma, immunosuppressant such as cyclosporine, intravenous immunoglobulin, etc., have.
However, since atopic diseases such as atopic dermatitis are difficult to cure and require a long period of time for treatment, it is required to develop a medicament that is easy to take while having few side effects even in long-term treatment.
On the other hand, the inventors of the present invention have reported that the glutinous rice extract exhibits excellent anti-inflammatory action against intestinal tissue (Korean Patent Application No. 10-2013-0008148, 2013).
Furthermore, the present inventors have reported that the external preparation containing the glutinous rice extract and tea extract as an active ingredient exhibits excellent dermatitis improving effect in a mouse model (Korean Patent No. 10-1477863, 2014).
However, there is no research on the effect of glutinous rice extract on atopy when taken orally, and there is no research on anti-atopic active substances contained in glutinous rice extract.
The present invention is directed to a composition for the treatment and prevention of atopic diseases. More specifically, it is an object of the present invention to provide a therapeutic agent useful for the treatment and prevention of an atopic disease by confirming the protective effect against the atopic disease of the rice extract and isolating and confirming the active ingredient in the rice extract.
In order to solve the above problems, the inventors of the present invention have studied the effect of water extract of glutinous rice on atopic diseases and studied the substances having anti-atopic activity which is effective for oral administration from glutinous rice extract. It has been found that the rice prolacomin protein contained in rice is the main ingredient exhibiting such anti-atopic activity, thus completing the present invention.
Accordingly, the present invention provides an oral composition having excellent anti-atopic activity with little side effects even with long-term use.
That is, the present invention relates to the following.
1. An oral anti-atopic composition comprising rice prolamin as an active ingredient.
2. The oral anti-atopic composition according to 1 above, wherein the composition comprises 0.01% or more rice flouramine.
3. The oral anti-atopic composition according to 1 above, wherein the rice prolamin is glutinous rice prolamin or rice flouramine.
4. The oral anti-atopic composition according to 1 above, wherein the rice prolamin is formulated in a form contained in rice extract.
The composition according to the present invention exhibits excellent anti-atopic effect in a model of atopic dermatitis mice. Since the protein of rice, which is a commercial food, is contained as an active ingredient, .
FIG. 1 summarizes the intake of rice extract (glutinous rice water extract or rice prolamine) and the schedule of DNCB treatment in BALB / c mice.
Fig. 2 shows that the glutinous rice water extract inhibited the symptoms of atopic dermatitis induced by DNCB in mice in a concentration-dependent manner.
FIG. 3 shows that the glutinous rice water extract inhibited the decrease in the skin barrier function induced by DNCB in mice in a concentration-dependent manner.
FIG. 4 shows the concentration-dependent inhibition of DNCB-induced increase in serum IgE concentration in mice by the glutinous rice water extract.
FIG. 5 shows electrophoresis (SDS-PAGE) of a fraction of the glutinous rice powder and the fraction of refolded rice powder.
Fig. 6 shows the concentration-dependent inhibition of glutinous rice prolamin in atopic dermatitis caused by DNCB in mice.
FIG. 7 shows that the increase in serum IgE concentration induced by DNCB in mice was inhibited in an amount dependent on the intake of glutinous rice prolacomin.
FIG. 8 shows that the symptoms of atopic dermatitis induced by DNCB in mice are suppressed to a similar extent to that of glutinous rice prolain and rice flouramin, and that the dermatitis inhibitory activity does not decrease even when heated at 100 ° C for 30 minutes.
FIG. 9 shows that the increase in the serum IgE concentration induced by DNCB in mice is similar to that of glutinous rice prolain and rice flouramin, and that even when they are heated at 100 ° C for 30 minutes, the inhibitory activity against IgE concentration increase does not decrease .
The rice prola- mine used in the composition of the present invention is a protein contained in rice and is composed of polypeptides having molecular weights of about 13 kDa, 16 kDa and 10 kDa, among which 13 kDa kinds are mostly in quantity.
Rice prolamin, the active ingredient of the anti-atopic composition of the present invention, can be purified from glutinous rice or rice flour.
In order to measure the anti-atopic activity of the composition of the present invention, BALB / c mice were fed a diet containing glutinous rice water (water) extract or refined rice prolamine for 6 weeks while injecting 2,4-dinitrochlorobenzene (DNCB) was applied to induce atopic dermatitis and the effects of rice glutinous rice extract and rice prolamine on dermatitis were examined.
As a result, glutinous rice water extract and rice prolain exhibited remarkable anti-atopic effect. In the case of rice prolamin, prolacomin extracted from glutinous rice and prylamin extracted from rice showed similar anti-atopic effect. In addition, even when rice floramine was heated at 100 ° C for 30 minutes, its anti-atopic activity did not decrease. Based on the above experimental results, the present invention has been completed in order to provide an oral anti-atopic composition comprising rice frylamine as a main ingredient.
The composition may be formulated into a dosage form for oral administration, and the composition for oral administration of the present invention may contain a pharmaceutically acceptable carrier. Oral formulations include solid forms such as tablets, capsules, powders, and granules, and may be formulated in liquid form.
The concentration of rice floramine contained in the composition is preferably 0.01% or more.
Hereinafter, the present invention will be described in more detail through the following examples and test examples. However, the following examples and test examples are provided only for illustrating the present invention, and the scope of the present invention is not limited thereto.
Example 1: Preparation of glutinous rice water (water) extract
Five times the weight of distilled water was added to 600 g of glutinous rice powder (brand name: Baekhon) and the mixture was shaken for 30 seconds with a blender for 3 times. After shaking, the mixture was centrifuged at 1,300 × g for 10 minutes to obtain supernatant, which was then freeze-dried and used as a glutinous rice water extract. The above procedure was repeated 5 times to obtain 235.8 g of glutinous rice water extract from 3.0 kg of glutinous rice powder.
Example 2: Preparation of rice < RTI ID = 0.0 >
The propranamine protein was extracted from glutinous rice (product name: Baek Ok-cheol) and rice (brand name: shinuri) powder by slightly modifying the method described by Ju et al. (J Food Sci. 66, 229-232, 2001). That is, 1 kg of rice powder was degreased with 4 liters of hexane and dried in a hood for 24 hours. The defatted rice powder was suspended in 4 L of 5% NaCl solution, shaken for 4 hours, and centrifuged at 3,000 xg for 30 minutes to remove the albumin-globulin fraction from the upper layer. The precipitate was again suspended in 4 L of 5% NaCl and the albumin-globulin removal procedure was repeated. Then, the precipitate was suspended in 3 liters of 70% ethanol and shaken for 4 hours, and the prolamin was extracted and centrifuged at 3,000 × g for 30 minutes to obtain the upper layer of the prolamin fraction. The precipitate was again suspended in 3 liters of 70% ethanol and the prolamin extraction procedure was repeated. Ethanol was removed from the extracted fractions of the propylamine under reduced pressure and centrifuged to obtain a precipitate. This precipitate was sufficiently dissolved with 50 ml of 25 mM NaOH solution, centrifuged, and ethanol was added to make the ethanol concentration 70%, and neutralized to
Example 3: Heat treatment of rice prolamin
0.5 g of each of the glutinous rice froramine and the rice frylamine prepared in Example 2 was suspended in 50 ml of distilled water, and the mixture was heated in boiling water for 30 minutes, cooled, lyophilized, and then used in the experiment.
Experimental Example 1: Protective effect of rice extract on DNCB-induced atopic dermatitis in mice
1) Experimental method
(1) Animals and Reagents
Six-week-old female BALB / c mice were purchased from a central laboratory animal (Seoul, Korea) and were allowed to freely consume water and feed while growing in a 12-hour night-day cycle, constant temperature and humidity conditions. The feed was prepared by powdering the product R03 of SAFE Lab Diets (Augy, France) and adding the rice glutinous rice water extract and rice prolamine powder prepared in Example 1-3 to 1-10% and 0.01-0.1%, respectively Were fed to mice and fresh feed was added daily. DNCB was purchased from Sigma-Aldrich (St. Louis, Mo., USA) and dissolved in acetone-olive oil (4: 1 / v: v).
(2) Measurement of atopic dermatitis defense effect
Figure 1 summarizes the intake of rice extract (glutinous rice water extract or rice prolacomin) and the schedule of DNCB treatment. In other words, feeds containing rice extracts were given to the
0 points: No symptoms
1 point: Weak symptoms
2 points: a little severe symptoms
3 points: severe symptoms
(3) Measurement of transdermal water loss (TEWL)
In order to observe changes in skin barrier function and the effect of rice extracts on the development of atopic dermatitis, the degree of transdermal water loss was measured. It was measured on the 14th day after DNCB treatment (+14 days) with Tewameter TM300 Khazaka Electronic GmbH, Koln, Germany).
(4) Measurement of serum immunoglobulin E (IgE) concentration
Since the degree of atopic dermatitis is known to be related to the serum IgE concentration, the change of serum IgE concentration was observed in the DNCB treated mice according to the rice extract intake. For this, blood was collected from the heart puncture under anesthesia 14 days after DNCB treatment (+14 days), serum was separated and stored at -80 ° C. Serum IgE concentrations were measured by sandwich ELISA using kit (eBioscience, San Diego, Calif., USA).
(5) Statistical analysis
The results were expressed as means ± SD. The significance test was performed according to the one-way ANOVA and the Scheffe test.
2) Test result
(1) Effect of glutinous rice water extract on DNCB induced atopic dermatitis
The glutinous rice water extracts prepared in Example 1 were added to feeds at 1, 3, and 10%, respectively, and the effects on DNCB-induced atopic dermatitis were measured in mice. In order to evaluate the effect on atopic dermatitis, we observed not only dermatitis symptom but also skin barrier function accompanied by dermatitis and the change of serum IgE concentration in atopic disease. The experimental results are shown in FIGS. 2, 3 and 4. The number of mice in each experimental group was 6, and * p <0.05 and ** p <0.01 indicate the significance of difference relative to the DNCB control.
As shown in FIG. 2, the mice were treated with DNCB to show severe dermatitis symptoms. At this time, when the glutinous rice water extract was added to the feed, the symptoms of dermatitis caused by DNCB were suppressed depending on the amount of glutinous rice water extract. Feeds containing 1% glutinous rice water extract did not show any significant inhibitory effect, but feedstuffs supplemented with 3 - 10% of them showed a remarkable inhibitory effect. In addition, as shown in FIG. 3, the treatment of mice with DNCB significantly increased transdermal water loss, which means that the skin barrier function was significantly reduced. At this time, the water content of the glutinous rice water was inhibited by DNCB at a concentration of 3-10%. In addition, as shown in FIG. 4, when the mice were treated with DNCB, the serum IgE concentration was greatly increased. When the rice water extract was taken, the increase of serum IgE concentration by DNCB was suppressed depending on the intake.
As a result, atopic dermatitis was significantly induced by DNCB treatment in mice, and at that time, ingestion of glutinous rice water extract significantly inhibited the development of atopic dermatitis
(2) Effects of glutinous rice propranamine on DNCB induced atopic dermatitis
First, the rice froramine fraction purified in Example 2 was subjected to electrophoresis (SDS-PAGE) according to the method of Laemmli (Nature 192, 680-682, 1970). Fig. 5 shows electrophoresis results obtained by adding 20 μg and 10 μg of glutinous rice prolacomin and rice flouramine to 15% polyacrylamide gel, respectively. These samples represent a main polypeptide band with a molecular weight of about 13 kDa, which is consistent with the structural properties of rice prolamine. Therefore, it was confirmed that the sample prepared from glutinous rice and rice in Example 2 is a highly purified prolamin protein.
Glutamic acid was added to feed to 0.01, 0.03, and 0.1%, respectively, and the effect of DNCB on atopic dermatitis and serum IgE levels were measured. The above experimental results are shown in Figs. 6 and 7, respectively. The number of mice in each experimental group was 6, and * p <0.05 and ** p <0.01 indicate the significance of difference relative to the DNCB control.
As a result, as shown in FIG. 6, glutinous rice prolain suppressed dermatitis symptoms by concentration-dependently at a concentration of 0.01-0.1%. In addition, as shown in FIG. 7, when the glutinous rice prolacomin was consumed, the increase in serum IgE concentration by DNCB was suppressed depending on the intake amount.
These results suggest that the use of glutinous rice propranamine instead of glutinous rice water extract significantly suppresses the development of atopic dermatitis caused by DNCB in mice.
(3) Comparison of anti-atopic activity of glutinous rice prolamin and rice flourylamine and heat resistance test of anti-atopic activity
According to Ahn et al. (Korean Patent No. 10-0963339, 2010), rice prola- mine protects gastric mucosal damage caused by harmful factors such as ethanol. In this case, prola- mine purified from glutinous rice is less than prola- mine refined from rice And exhibited high specific activity. Therefore, in the present invention, the anti-atopic activity of glutinous rice prolamin and rice flourylamine was compared.
To this end, the glutinous rice prola- mine and the rice flouramine prepared in Example 2 were added to feeds at 0.05%, respectively, and the effects on DNCB-induced atopic dermatitis and serum IgE concentrations were measured . In order to observe the heat resistance of these rice prolamines, glutinous rice prola- mine and rice flouramine were heat-treated at 100 ° C for 30 minutes as in Example 3, and then added to the feed to 0.05% The effect of DNCB on atopic dermatitis and serum IgE concentration was measured. The above results are shown in Figs. 8 and 9. The number of mice in each experimental group was 6, and ** p <0.01 indicates the significance of difference from the DNCB control group.
As shown in FIG. 8 and FIG. 9, not only glutinous rice prolain but also rice flourolamine significantly suppressed dermatitis symptoms and serum IgE concentration by 0.05% of DNCB, and the inhibitory effect of both prolacomin was similar.
In addition, even when the glutinous rice prola- mine and the rice flourylamine were heated at 100 ° C for 30 minutes, the anti-atopic activity before heating was maintained.
These results suggest that both glutinous rice flouramine and rice flouryl pyrophosphate have similar anti - atopic activity and that their activity is highly resistant to high temperature such as cooking process.
Claims (4)
Wherein the composition contains 0.01% or more rice flouramine.
An oral anti-atopic composition wherein the rice prolamin is glutinous rice prolamin or rice flouramin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140100619 | 2014-08-05 | ||
| KR20140100619 | 2014-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160017607A true KR20160017607A (en) | 2016-02-16 |
Family
ID=55264070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150101592A KR20160017607A (en) | 2014-08-05 | 2015-07-17 | Oral anti-atopic preparations comprising rice prolamin |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20160017607A (en) |
| WO (1) | WO2016021847A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102460545B1 (en) | 2020-02-18 | 2022-10-31 | 주식회사 피코엔텍 | Asthma Suppressant which Contains mutant saccharomyces cerevisiae |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0873367A (en) * | 1994-09-07 | 1996-03-19 | Soken Kk | Agent for prophylaxis and treatment of atopic dermatitis produced from rice |
| KR100963339B1 (en) * | 2008-04-02 | 2010-06-14 | 다산엠앤에프(주) | Anti-peptic ulcer preparation comprising rice prolamin |
| TWI411442B (en) * | 2010-01-28 | 2013-10-11 | Mackay Memorial Hospital | Application of Glutenin in Inhibiting Leukemia |
| KR101477863B1 (en) * | 2012-09-28 | 2014-12-30 | 전남대학교산학협력단 | An external preparation with anti-atopic dermatitis activity comprising glutinous rice and tea extracts |
| CN103877413B (en) * | 2014-03-19 | 2016-12-07 | 青岛市市立医院 | A kind of pharmaceutical composition treating Oral diseases |
-
2015
- 2015-07-17 KR KR1020150101592A patent/KR20160017607A/en not_active Application Discontinuation
- 2015-07-17 WO PCT/KR2015/007448 patent/WO2016021847A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016021847A1 (en) | 2016-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101947126B1 (en) | Plant extracts for the treatment and prevention of infections | |
| RU2423139C2 (en) | COMPOSITION CONTAINING Actinidia AND METHODS OF THEIR APPLICATION | |
| US20130337090A1 (en) | Plant extracts for treating burns and chronic wounds | |
| WO2016159593A2 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases, containing lactococcus chungangensis as active ingredient | |
| Lee et al. | Triticum aestivum sprout extract attenuates 2, 4‑dinitrochlorobenzene‑induced atopic dermatitis‑like skin lesions in mice and the expression of chemokines in human keratinocytes | |
| WO2016190661A1 (en) | Cosmetic composition for inhibiting pruritus and alleviating atopic dermatitis, containing isosecotanapartholide as active ingredient | |
| US11141449B2 (en) | Method of extracting flavonoids and/or polyphenols from dried and powdered citrus peels, compositions therefrom, and methods of treatment of diseases associated with chronic inflammation | |
| KR20060093626A (en) | Anti-atopy and/or anti-itching composition containing african phellinus mushroom extract | |
| Zorko et al. | Efficacy of a polyphenolic extract from silver fir (Abies alba) bark on psoriasis: A randomised, double-blind, placebo-controlled trial | |
| JP2021176888A (en) | Therapeutic pharmaceutical composition comprising purple corn extract for prevention or treatment of skin disease | |
| KR101734093B1 (en) | A pharmaceutical composition for preventing and treating inflammatory disease containing the purified bee venom which was reduced allergen, as a active ingredient | |
| US20080175888A1 (en) | Combination Therapy Comprising Actinidia and Steroids and Uses Thereof | |
| KR20110125087A (en) | A composition comprising extract from herbal for improving pruritus | |
| KR20160017607A (en) | Oral anti-atopic preparations comprising rice prolamin | |
| EP3097920B1 (en) | Medical composition comprising stauntonia hexaphylla extract | |
| KR101809800B1 (en) | A pharmaceutical composition comprising anti-allergic peptide isolated from abalone intestine | |
| AU2015220485B2 (en) | Fractions of extracts of Helichrysum having mucohadesive properties | |
| KR102119795B1 (en) | Anti-inflammatory Composition Comprising Broccoli Extract | |
| JP2018522923A (en) | Slimming and skin care composition and method for preparing the same | |
| KR101424105B1 (en) | Composition for improvement of pruritus containg bee venom | |
| KR102382067B1 (en) | Composition for treating atopic dermatitis comprising Complex extract of Schizonepeta Tenuifolia Briq. and Alpinia Oxyphylla Miq. as an active ingredient | |
| KR101749668B1 (en) | Composition for preventing or treating of allergic skin disease comprising root extract of Rubus coreanus as an active ingredient | |
| KR20150075497A (en) | Persicaria thunbergii extract for allergic diseases and process for preparation thereof | |
| KR20200074308A (en) | A composition for preventing or treating atopy comprising the extract of Artemisia Anomala | |
| TW201400128A (en) | Plant extracts for the treatment and prevention of infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |